Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention AI-powered digital twins, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention AI-powered digital twins, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. Their average consequence score of 6 runs above the beat's 5.7 for that window. Dr. Edward Baidoo appears in 1 tracked Biotech story from August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Edward Baidoo. Shared-story counts are live from our verified record — not editorial picks.
eXoZymes lands a high-profile DOE grant to develop AI digital twins for cell-free enzyme manufacturing. The 9-month collaboration with Lawrence Berkeley Lab could slash process development timelines and unlock faster routes for nutraceuticals and novel therapeutics.
Source: californiatelegraph.com · hawaiitelegraph.com
Dr. Edward Baidoo is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
